ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 744

Prediction of All-Cause Mortality and Pulmonary Arterial Hypertension (PAH) Progression in Systemic Sclerosis (SSc), an Echocardiography Study

Anders Heiervang Tennøe1, Anna-Maria Hoffmann-Vold1, Øyvind Molberg1, Håvard Fretheim1, Torhild Garen1, Einar Gude1, Arne K Andreassen1, Klaus Murbræch2, Svend Aakhus3, Johanna Andreassen2 and Oyvind Midtvedt1, 1Oslo University Hospital, Oslo, Norway, 2Cardiology, Oslo University Hospital, Oslo, Norway, 3Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in systemic sclerosis (SSc). Annual echocardiograms (echo) are recommended to detect PAH at an early stage, potentially improving outcome. We aimed to evaluate the potential of baseline echo parameters to predict PAH progression and all-cause mortality.

Methods: The study cohort included all SSc patients from the prospective Oslo University Hospital (OUH) cohort who had an evaluable baseline protocol echo performed between 2003 and 2016. This echo was analyzed regarding left- and right-sided systolic and diastolic function. Right heart catheterization (RHC) was performed in patients suspected of PH. PAH diagnosis was made by an experienced cardiologist with mean pulmonary artery pressure ≥ 25 mmHg, pulmonary capillary wedge pressure <15mmHg, stable forced vital capacity >70% and <10% lung fibrosis on HRCT. Vital status was available for all patients and PAH progression, defined by occurrence of new PAH related events were calculated. Cox regression analyzes were conducted.

Results: In total, 337 SSc patients with baseline echo were included. RHC was conducted in 149 (44.2%) patients and 48 (14.2%) were diagnosed with PAH; of those, 34 patients showed PAH progression. Demographic and clinical characteristics are summarized in Table 1. Significant results from univariable and multivariable cox analyses of death are shown in Table 2, and for PAH progression in Table 3. In the final cox regression model for death, age (HR 1.06, 1.03-1.10 95%CI , p<0.001), DLCO (HR 0.97, 0.96-0.98 95%CI , p=0.001), pericardial effusion (HR 2.24, 1.37-3.63 95%CI , p<0.001), left atrium area (HR 1.07, 1.01-1.14 95% CI, p=0.024) and tricuspid annular plane systolic excursion (TAPSE) (HR 0.38, 0.19-0.74 95% CI , p=0.004) were associated (c-index 0.82). PAH progression was associated with age (HR 1.06, 1.02-1.11 95% CI, p=0.005), DLCO (HR 0.97, 0.95-0.99 95% CI, p=0.002), and right atrium area (HR 1.17, 1.10-1.25 95% CI, p<0.001) (c-index 0.86).

Conclusion: In our large and unselected SSc cohort, impaired baseline right heart function, but not left ventricular systolic or diastolic parameters, was predictive for both death and PAH progression. Echo may serve as a tool to stratify patients at risk for PAH and death.

 

Table 1: Demographic and clinical characteristics of all SSc patients, SSc-PAH patients and deceased patients.

 

 

 

 

 

All cases (n=337)

Deceased patients (n=101)

PAH

(n=48)

Male, no (%)

57 (17)

25 (25)

8 (17)

ACA, no (%)

172 (55)

39 (39)

38 (83)

lcSSc, no (%)

224 (68)

65 (64)

44 (92)

Death, no (%)

101 (30)

–

25 (52)

Age at echo, mean (SD)

58 (14)

64 (12)

64 (11)

Observation period, years, median (min,max)

5.1 (0-14)

3.0 (0-12)

5.3 (0.1-12.3)

TAPSE, cm (SD)

2.3 (0.5)

2.0 (0.6)

2.0 (0.6)

Right ventricular strain % (SD)

23.0 (6.1)

20.3 (7.1)

19.3 (7.3)

Left atrium area, cm2 (SD)

18 (5)

19 (5)

17 (4)

LV Global longitudinal strain, % (SD)

18.4 (3.0)

17.6 (3.5)

18.4 (2.2)

LVEF, % (SD)

58 (8)

56 (10)

59 (7)

E-wave, m/s (SD)

0.72 (0.21)

0.72 (0.29)

0.67(0.24)

A-wave, m/s (SD)

0.70 (0.22)

0.77 (0.26)

0.72(0.21)

e’ septal, cm/s (SD)

7.5 (2.6)

5.9 (2.1)

5.7 (2.1)

E/e’ ratio (SD)

10.6 (4.5)

13.0 (6.3)

12.7 (6.1)

Tricuspid regurgitant pressure (TRp) , mmHg (SD)

34 (21)

44 (25)

50 (26)

Right atrium, area, cm2 (SD)

17 (6)

19 (7)

21 (8)

Fractional area change (FAC), % (SD)

39 (10)

35 (10)

32 (11)

Pericardial effusion, no (%)

42 (13)

22 (22)

9 (19)

 

Table 2: Univariable and multivariable cox regression analyses associated with death

 

 

 

 

Univarable

Multivariable

 

HR

95% CI

p-value

HR

95% CI

p-value

Pericardial effusion

2.09

1.49-2.94

<0.001

1.86

1.18-2.95

0.008

Left atrium, area

1.05

1.01-1.05

0.017

1.08

1.02-1.14

0.008

TAPSE

0.29

0.19-0.45

<0.001

0.44

0.23-0.83

0.011

Right ventricular strain

0.93

0.89-0.98

0.002

0.94

0.88-0.99

0.045

Right atrium, area

1.08

1.05-1.12

<0.001

1.1

1.05-1.15

<0.001

TRp

1.02

1.01-1.03

<0.001

1.02

1.002-1.02

0.019

 

Table 3: Univariable and multivariable cox regression analyses (adjusted for age and gender) associated with PAH progression

 

 

 

 

Univariable

Multivariable

 

HR

95% CI

p-value

HR

95% CI

p-value

Pericardial effusion

2.9

1.76-4.69

<0.001

3.2

1.83-5.55

<0.001

TAPSE

0.17

0.09-0.34

<0.001

0.24

0.12-0.47

<0.001

Right ventricular strain

0.89

0.85-0.95

0.001

0.89

0.84-0.95

<0.001

Right atrium, area

1.17

1.11-1.22

<0.001

1.14

1.08-1.20

<0.001

FAC

0.93

0.89-0.96

<0.001

0.94

0.90-0.97

0.001

 


Disclosure: A. Heiervang Tennøe, None; A. M. Hoffmann-Vold, None; Ø. Molberg, None; H. Fretheim, None; T. Garen, None; E. Gude, None; A. K. Andreassen, None; K. Murbræch, None; S. Aakhus, None; J. Andreassen, None; O. Midtvedt, None.

To cite this abstract in AMA style:

Heiervang Tennøe A, Hoffmann-Vold AM, Molberg Ø, Fretheim H, Garen T, Gude E, Andreassen AK, Murbræch K, Aakhus S, Andreassen J, Midtvedt O. Prediction of All-Cause Mortality and Pulmonary Arterial Hypertension (PAH) Progression in Systemic Sclerosis (SSc), an Echocardiography Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prediction-of-all-cause-mortality-and-pulmonary-arterial-hypertension-pah-progression-in-systemic-sclerosis-ssc-an-echocardiography-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-all-cause-mortality-and-pulmonary-arterial-hypertension-pah-progression-in-systemic-sclerosis-ssc-an-echocardiography-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology